138 related articles for article (PubMed ID: 36912019)
1. Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil.
Mendes JC; Braga MDG; Reis AMM; Silveira MR
Curr Med Res Opin; 2023 Apr; 39(4):523-531. PubMed ID: 36912019
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Mendes JC; Bonolo PF; Ceccato MDGB; Costa JO; Reis AMM; Dos Santos H; Silveira MR
Eur J Clin Pharmacol; 2018 Aug; 74(8):1077-1088. PubMed ID: 29740676
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
[TBL] [Abstract][Full Text] [Related]
4. Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Rodrigues VA; Ceccato MDGB; de Oliveira Costa J; Almeida-Brasil CC; Silveira MR; Afonso Reis E
AIDS Care; 2023 Jul; 35(7):976-981. PubMed ID: 35635108
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
6. Active Pharmacovigilance Project on the safety profile of Dolutegravir in Brazil.
Mendes JC; Ceccato MDGB; Reis AMM; Costa AMGD; Pantuzza LLN; Furtado Dos Santos S; Crepalde-Ribeiro K; Silveira MR
AIDS Care; 2023 May; 35(5):729-738. PubMed ID: 35578399
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
Fernández-Bargiela N; Rotea-Salvo S; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Míguez-Rey E; Cid-Silva P
Eur J Hosp Pharm; 2022 Jul; 29(4):207-211. PubMed ID: 33051194
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Eluwa GI; Badru T; Agu KA; Akpoigbe KJ; Chabikuli O; Hamelmann C
BMC Clin Pharmacol; 2012 Feb; 12():7. PubMed ID: 22369677
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.
Abah IO; Akanbi M; Abah ME; Finangwai AI; Dady CW; Falang KD; Ebonyi AO; Okopi JA; Agbaji OO; Sagay AS; Okonkwo P; Idoko JA; Kanki PJ
Germs; 2015 Sep; 5(3):83-91. PubMed ID: 26405676
[TBL] [Abstract][Full Text] [Related]
13. Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
Chapola JC; Lee F; Bula A; Rosenberg NE; Tseka J; Chagomerana M; Hosseinipour MC; Tang JH
BMC Womens Health; 2023 Sep; 23(1):478. PubMed ID: 37689628
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Rutherford GW; Horvath H
PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
[TBL] [Abstract][Full Text] [Related]
15. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
[TBL] [Abstract][Full Text] [Related]
16. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Jiang J; Xu X; Guo W; Su J; Huang J; Liang B; Chen H; Zang N; Liao Y; Ye L; Liang H
AIDS Res Ther; 2016; 13(1):30. PubMed ID: 27617024
[TBL] [Abstract][Full Text] [Related]
18. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
19. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
Law JKC; Butler LT; Hamill MM
AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
